CoChat

Cardiac matrix: A clue for future therapy

Mishra, Paras Kumar, Givvimani, Srikanth, Chavali, Vishalakshi, Tyagi, Suresh C. · 2013 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Cited by 49

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2013.09.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 73

  1. Engler, 2006, Matrix elasticity directs stem cell lineage specification, Cell, 126, 677, 10.1016/j.cell.2006.06.044 · DOI · Paper page
  2. Kajstura, 2008, The human heart: a self-renewing organ, Clin. Transl. Sci., 1, 80, 10.1111/j.1752-8062.2008.00030.x · DOI
  3. Bolli, 2011, Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial, Lancet, 378, 1847, 10.1016/S0140-6736(11)61590-0 · DOI · Paper page
  4. Hu, 2011, Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation, Circulation, 124, S27, 10.1161/CIRCULATIONAHA.111.017954 · DOI · Paper page
  5. Tyagi, 2011, Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases, Curr. Diabetes Rev., 7, 367, 10.2174/157339911797579179 · DOI
  6. Mishra, 2010, MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA, Cell Biochem. Biophys., 57, 67, 10.1007/s12013-010-9084-1 · doi:10.1007/s12013-010-9084-1
  7. Mishra, 2012, Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix, Can. J. Physiol. Pharmacol., 90, 353, 10.1139/y11-131 · DOI
  8. Mishra, 2010, Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol, Cardiovasc. Diabetol., 9, 49, 10.1186/1475-2840-9-49 · DOI
  9. Tyagi, 1993, Myocardial matrix metalloproteinase(s): localization and activation, Mol. Cell. Biochem., 126, 49, 10.1007/BF01772207 · DOI
  10. Dhanaraj, 1996, X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily, Structure, 4, 375, 10.1016/S0969-2126(96)00043-3 · DOI
  11. Bernstein, 1998, Data-based approach for developing a physical activity frequency questionnaire, Am. J. Epidemiol., 147, 147, 10.1093/oxfordjournals.aje.a009427 · DOI · Paper page
  12. Moshal, 2008, Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia, Am. J. Physiol. Heart Circ. Physiol., 295, H890, 10.1152/ajpheart.00099.2008 · DOI
  13. Moshal, 2008, Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia, Curr. Vasc. Pharmacol., 6, 84, 10.2174/157016108783955301 · doi:10.2174/157016108783955301
  14. Givvimani, 2010, MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure, Arch. Physiol. Biochem., 116, 63, 10.3109/13813451003652997 · DOI
  15. Ma, 2004, Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene, J. Biol. Chem., 279, 46326, 10.1074/jbc.M405438200 · DOI
  16. Qin, 1999, The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells, J. Biol. Chem., 274, 29130, 10.1074/jbc.274.41.29130 · DOI · Paper page
  17. Gutierrez, 2008, Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection, J. Infect. Dis., 197, 1468, 10.1086/587487 · DOI
  18. Wang, 2006, Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility, Cardiovasc. Res., 69, 688, 10.1016/j.cardiores.2005.08.023 · DOI
  19. Li, 1996, Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions, Am. J. Pathol., 148, 121
  20. Lovett, 2012, A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity, PLoS One, 7, e34177, 10.1371/journal.pone.0034177 · DOI
  21. Libby, 2000, Matrix matters, Circulation, 102, 1874, 10.1161/01.CIR.102.16.1874 · DOI · Paper page
  22. Libby, 2001, Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 10.1161/01.CIR.104.3.365 · DOI · Paper page
  23. Spoto, 2012, Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure, Nephrol. Dial. Transplant., 27, 2440, 10.1093/ndt/gfr710 · doi:10.1093/ndt/gfr710
  24. Seo, 2011, An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo, Peptides, 32, 1840, 10.1016/j.peptides.2011.08.010 · DOI
  25. Seo, 2003, TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism, Cell, 114, 171, 10.1016/S0092-8674(03)00551-8 · DOI · Paper page
  26. Kallio, 2011, TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway, Int. J. Cancer, 128, 991, 10.1002/ijc.25404 · DOI
  27. Finan, 2006, In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2, Lung Cancer, 53, 273, 10.1016/j.lungcan.2006.06.006 · DOI
  28. Koskivirta, 2010, Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload, J. Biol. Chem., 285, 24487, 10.1074/jbc.M110.136820 · DOI · Paper page
  29. Ahmed, 2006, Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease, Circulation, 113, 2089, 10.1161/CIRCULATIONAHA.105.573865 · DOI · Paper page
  30. Spinale, 2013, Membrane-associated matrix proteolysis and heart failure, Circ. Res., 112, 195, 10.1161/CIRCRESAHA.112.266882 · DOI · Paper page
  31. Peterson, 2001, Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure, Circulation, 103, 2303, 10.1161/01.CIR.103.18.2303 · DOI · Paper page
  32. Rizzi, 2010, Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension, J. Card. Fail., 16, 599, 10.1016/j.cardfail.2010.02.005 · DOI
  33. Rizzi, 2013, Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy, Exp. Mol. Pathol., 94, 1, 10.1016/j.yexmp.2012.10.010 · DOI
  34. Ferraz, 2013, Recombinant human matrix metalloproteinase-2 impairs cardiovascular beta-adrenergic responses, Basic Clin. Pharmacol. Toxicol., 112, 103, 10.1111/bcpt.12001 · DOI
  35. Phatharajaree, 2007, Matrix metalloproteinases and myocardial infarction, Can. J. Cardiol., 23, 727, 10.1016/S0828-282X(07)70818-8 · DOI
  36. Neto-Neves, 2013, Matrix metalloproteinases as drug targets in acute pulmonary embolism, Curr. Drug Targets, 14, 344
  37. Neto-Neves, 2011, Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism, Crit. Care Med., 39, 349, 10.1097/CCM.0b013e3181fa3dfe · DOI
  38. Sousa-Santos, 2012, Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism, Naunyn Schmiedebergs Arch. Pharmacol., 385, 685, 10.1007/s00210-012-0748-9 · DOI
  39. Castro, 2011, Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases, Pharmacol. Res., 64, 551, 10.1016/j.phrs.2011.05.005 · DOI
  40. Yamada, 2000, ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs, Inflamm. Res., 49, 144, 10.1007/s000110050573 · DOI
  41. Golub, 1987, A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity, J. Dent. Res., 66, 1310, 10.1177/00220345870660080401 · DOI · Paper page
  42. Richards, 2011, Antimicrobial and non-antimicrobial tetracyclines in human cancer trials, Pharmacol. Res., 63, 151, 10.1016/j.phrs.2010.10.008 · DOI
  43. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  44. Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 · DOI · Paper page
  45. Mishra, 2009, MicroRNAs as a therapeutic target for cardiovascular diseases, J. Cell. Mol. Med., 13, 778, 10.1111/j.1582-4934.2009.00744.x · DOI · Paper page
  46. Pelouch, 1993, Role of extracellular matrix proteins in heart function, Mol. Cell. Biochem., 129, 101, 10.1007/BF00926359 · DOI · Paper page
  47. Tyagi, 1997, Proteinases and myocardial extracellular matrix turnover, Mol. Cell. Biochem., 168, 1, 10.1023/A:1006850903242 · DOI
  48. Tyagi, 1996, Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy, J. Mol. Cell. Cardiol., 28, 1415, 10.1006/jmcc.1996.0132 · DOI
  49. Ovechkin, 2005, Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice, J. Appl. Physiol., 99, 2398, 10.1152/japplphysiol.00442.2005 · DOI
  50. Pavlovsky, 1999, X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity, Protein Sci., 8, 1455, 10.1110/ps.8.7.1455 · DOI
  51. Care, 2007, MicroRNA-133 controls cardiac hypertrophy, Nat. Med., 13, 613, 10.1038/nm1582 · DOI · Paper page
  52. Matkovich, 2010, MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts, Circ. Res., 106, 166, 10.1161/CIRCRESAHA.109.202176 · DOI · Paper page
  53. Chavali, 2012, MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes, Biochem. Biophys. Res. Commun., 425, 668, 10.1016/j.bbrc.2012.07.105 · DOI
  54. Mishra, 2010, Stem cells as a therapeutic target for diabetes, Front. Biosci., 15, 461, 10.2741/3630 · DOI
  55. Eitan, 2010, Acellular cardiac extracellular matrix as a scaffold for tissue engineering: in vitro cell support, remodeling, and biocompatibility, Tissue Eng. Part C Methods, 16, 671, 10.1089/ten.tec.2009.0111 · DOI · Paper page
  56. Friehs, 2006, Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis, Basic Res. Cardiol., 101, 204, 10.1007/s00395-005-0581-0 · DOI
  57. Sang, 1998, Complex role of matrix metalloproteinases in angiogenesis, Cell Res., 8, 171, 10.1038/cr.1998.17 · DOI · Paper page
  58. Brooks, 1998, Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity, Cell, 92, 391, 10.1016/S0092-8674(00)80931-9 · DOI · Paper page
  59. Brooks, 1996, Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3, Cell, 85, 683, 10.1016/S0092-8674(00)81235-0 · DOI · Paper page
  60. Sodha, 2009, Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation, Am. J. Physiol. Heart Circ. Physiol., 296, H428, 10.1152/ajpheart.00283.2008 · DOI
  61. Laham, 1999, Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial, Circulation, 100, 1865, 10.1161/01.CIR.100.18.1865 · DOI · Paper page
  62. Rosengart, 1999, Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA, Ann. Surg., 230, 466, 10.1097/00000658-199910000-00002 · DOI · Paper page
  63. Schumacher, 1998, Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease, Circulation, 97, 645, 10.1161/01.CIR.97.7.645 · DOI · Paper page
  64. Shiojima, 2005, Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, J. Clin. Invest., 115, 2108, 10.1172/JCI24682 · DOI · Paper page
  65. Givvimani, 2011, Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure, J. Appl. Physiol., 110, 1093, 10.1152/japplphysiol.01064.2010 · DOI
  66. Ducharme, 2000, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction, J. Clin. Invest., 106, 55, 10.1172/JCI8768 · DOI · Paper page
  67. Hua, 2012, Relationship between endothelial-to-mesenchymal transition and cardiac fibrosis in acute viral myocarditis, Zhejiang Da Xue Xue Bao Yi Xue Ban, 41, 298
  68. Kalluri, 2009, The basics of epithelial–mesenchymal transition, J. Clin. Invest., 119, 1420, 10.1172/JCI39104 · DOI · Paper page
  69. Zeisberg, 2007, Endothelial-to-mesenchymal transition contributes to cardiac fibrosis, Nat. Med., 13, 952, 10.1038/nm1613 · DOI · Paper page
  70. Yang, 2002, Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy, J. Clin. Invest., 110, 1525, 10.1172/JCI0216219 · DOI · Paper page
  71. Lefer, 2007, A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide, Proc. Natl. Acad. Sci. U.S.A., 104, 17907, 10.1073/pnas.0709010104 · DOI · Paper page
  72. Qipshidze, 2012, Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis, Int. J. Biol. Sci., 8, 430, 10.7150/ijbs.3632 · DOI
  73. Lin, 2012, Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair, Sci. Transl. Med., 4, 146ra109, 10.1126/scitranslmed.3003841 · DOI · Paper page

Cited by

Metadata

Authors
Mishra, P. K., Givvimani, S., Chavali, V., & Tyagi, S. C.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2013-12
Volume
1832
Issue
12
Pages
2271-2276
ISSN
0925-4439
Cited by
49
References
3
Language
en
Licence
Funders
  • American Heart Association (11BGIA 7690055)
  • National Institute of Health (HL-113281, HL-108621, HL-74185)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.